Olmesartan Medoxomil/Amlodipine Zentiva (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Amlodipine Zentiva, is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond what a single agent can provide.

GNH USA supplies Olmesartan Medoxil/Amlodipine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxil/Amlodipine combines two antihypertensive agents to lower blood pressure through complementary mechanisms. It is indicated for: - Hypertension: provides additional blood pressure reduction when monotherapy is insufficient. - Isolated systolic hypertension in the elderly: improves systolic control while maintaining tolerability. - Hypertensive patients with concomitant low‑dose calcium‑channel blocker therapy: offers a single‑pill regimen to simplify treatment.

Adverse reactions may occur with any antihypertensive combination. Patients should be aware of both common and less frequent events.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness: especially after standing. - Flushing: transient warmth sensation. - Fatigue: general tiredness. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips or throat. - Severe hypotension: symptomatic low blood pressure. - Hepatic dysfunction: elevated liver enzymes. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: elevated serum potassium levels. - Myocardial infarction: rare but reported in high‑risk patients.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: assess baseline creatinine and adjust if impaired. - Hepatic function: check liver enzymes in patients with liver disease. - Electrolytes: monitor potassium, especially if combined with potassium‑sparing agents. - Pregnancy: avoid use; teratogenic risk is associated with angiotensin‑II blockade. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil/Amlodipine may alter the effect of several concomitant medicines. Awareness of major and moderate interactions helps optimise safety.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade: avoid concurrent ACE inhibitors or other ARBs to prevent excess hypotension and renal injury. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase amlodipine levels, raising risk of edema and hypotension. - Lithium: increased lithium concentrations can lead to toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Diuretics: can potentiate hypotensive response; monitor blood pressure and electrolytes. - Potassium‑sparing diuretics or supplements: risk of hyper‑kalaemia, especially in renal impairment.